Balyasny Asset Management »

Enliven Therapeutics shares owned by Balyasny Asset Management

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by Balyasny Asset Management from 13F filings

Historical chart of Balyasny Asset Management investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by Balyasny Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by Balyasny Asset Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $12M 310k 39.20

More positions owned by Balyasny Asset Management

State Str Spdr S&p 500 Etf T Tr Unit Call Option (SPY)
Invesco Qqq Tr Unit Ser 1 Call Option (QQQ)
Ishares Tr Russell 2000 Etf Call Option (IWM)
Meta Platforms Cl A Call Option (META)
Amazon Call Option (AMZN)
NVIDIA Corporation Call Option (NVDA)
Apple Call Option (AAPL)
Alphabet Cap Stk Cl A Call Option (GOOGL)
Warner Bros Discovery Com Ser A Put Option (WBD)
Raytheon Technologies Corp Call Option (RTX)
Select Sector Spdr Tr State Street Fin Call Option (XLFI)
Select Sector Spdr Tr State Street Ene Call Option (XLE)
Lumentum Hldgs Note 0.500% 6/1 (Principal)
Microsoft Corporation Call Option (MSFT)
Ishares Tr Iboxx Hi Yd Etf Call Option (HYG)

View all positions for Balyasny Asset Management

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
BlackRock
Polar Capital Holdings
Commodore Capital
Vestal Point Capital
Vanguard Group
Citadel Advisors
Fairmount Funds Management
VR Adviser
Novo A/S
Geode Capital Management
State Street Corporation
Logos Global Management
Pictet Asset Management Holding SA

View all funds holding Enliven Therapeutics